Technical Analysis for BCYC - Bicycle Therapeutics plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Golden Cross | Bullish | 1.52% | |
Pocket Pivot | Bullish Swing Setup | 1.52% | |
Inside Day | Range Contraction | 1.52% | |
Fell Below 20 DMA | Bearish | 5.14% | |
New Downtrend | Bearish | 5.14% | |
Wide Range Bar | Range Expansion | 5.14% | |
Pocket Pivot | Bullish Swing Setup | -5.60% | |
NR7 | Range Contraction | -5.60% | |
Crossed Above 20 DMA | Bullish | -3.67% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 13 hours ago |
Rose Above Previous Day's High | about 13 hours ago |
Up 2% | about 13 hours ago |
Up 1% | about 16 hours ago |
Down 3% | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.9 |
52 Week Low | 12.54 |
Average Volume | 322,175 |
200-Day Moving Average | 20.61 |
50-Day Moving Average | 20.83 |
20-Day Moving Average | 24.62 |
10-Day Moving Average | 24.51 |
Average True Range | 1.48 |
RSI (14) | 54.55 |
ADX | 30.81 |
+DI | 20.67 |
-DI | 23.51 |
Chandelier Exit (Long, 3 ATRs) | 22.79 |
Chandelier Exit (Short, 3 ATRs) | 25.77 |
Upper Bollinger Bands | 26.59 |
Lower Bollinger Band | 22.66 |
Percent B (%b) | 0.37 |
BandWidth | 15.98 |
MACD Line | 0.97 |
MACD Signal Line | 1.35 |
MACD Histogram | -0.3839 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 26.21 | ||||
Resistance 3 (R3) | 26.07 | 25.23 | 25.86 | ||
Resistance 2 (R2) | 25.23 | 24.70 | 25.30 | 25.74 | |
Resistance 1 (R1) | 24.68 | 24.37 | 24.96 | 24.82 | 25.63 |
Pivot Point | 23.84 | 23.84 | 23.98 | 23.91 | 23.84 |
Support 1 (S1) | 23.29 | 23.31 | 23.57 | 23.43 | 22.61 |
Support 2 (S2) | 22.45 | 22.98 | 22.52 | 22.50 | |
Support 3 (S3) | 21.90 | 22.45 | 22.38 | ||
Support 4 (S4) | 22.04 |